Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Ascelia Pharma AB (publ) is a biotech company specializing in the development and commercialization of novel drugs for orphan oncology treatments. The company focuses on addressing unmet medical needs in rare cancer conditions through two key drug candidates: Orviglance, a novel non-gadolinium oral contrast agent for MRI scans of the liver, which has successfully met its primary endpoint in the pivotal Phase 3 SPARKLE study and is advancing toward a New Drug Application submission to the FDA; and Oncoral, an innovative oral irinotecan chemotherapy tablet in preparation for Phase 2 trials targeting gastric cancer. Orviglance improves visualization of focal liver lesions in patients with impaired kidney function, offering a safer alternative to gadolinium-based agents, while Oncoral aims to enhance patient outcomes with convenient daily dosing over traditional infusions. Headquartered in Malmö, Sweden, and founded in 1999, Ascelia Pharma plays a significant role in the oncology sector by advancing treatments with clear regulatory pathways and orphan drug designations, contributing to improved diagnostics and therapies for underserved patient populations in global markets.
kr 0.21
+kr 0.01 (+5.67%)
EOD Jun 23, 2026 · Twelve Data
Negative free cash flow of -kr 72M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 0.00
Net Income (TTM)
-kr 71M
▲ +4.7% YoY
Op. Margin
—
ROIC
-57.19%
▲ +2.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 71M
▼ -15.1% YoY
Op. Cash Flow (TTM)
-kr 67M
▼ -11.9% YoY
Net Debt
-kr 49M
Net Cash Position
Cash & Equiv.
kr 50M
Continue Research
Ascelia Pharma AB (publ) (ACE.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Ascelia Pharma AB (publ) scores 10/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Ascelia Pharma AB (publ) scores 10 out of 100 on Intrinsiqq's quality score, passing 1 of 4 checks, which makes it a lower-quality business on these measures. Recent fundamentals include a -57.2% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full check-by-check breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh ACE.XSTO's valuation and scores 10/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.